Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ImmuniT Platform for Improved Neoantigen Prediction in Lung Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Methods for Processing and Analyzing Images of Vascularized Micro-Organ and Tumor Systems.

bioRxiv : the preprint server for biology·2025
Same author

A Microphysiological HHT-on-a-Chip Platform Recapitulates Patient Vascular Lesions.

Research square·2024
Same author

Organotypic stromal cells impact endothelial cell transcriptome in 3D microvessel networks.

Scientific reports·2022
Same author

Slug regulates the Dll4-Notch-VEGFR2 axis to control endothelial cell activation and angiogenesis.

Nature communications·2020

Related Experiment Video

Updated: Jan 16, 2026

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K

ImmuniT Platform for Improved Neoantigen Prediction in Lung Cancer.

Stephanie J Hachey1, Alexander G Forsythe2, Hari B Keshava3

  • 1Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, USA.

Vaccines
|September 27, 2025
PubMed
Summary

ImmuniT enhances neoantigen discovery for lung cancer immunotherapy by identifying missed targets. This platform improves T cell activation, offering new hope for patients unresponsive to current treatments.

Keywords:
immunotherapylung carcinomaneoantigenpersonalized therapy

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K

Related Experiment Videos

Last Updated: Jan 16, 2026

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K

Area of Science:

  • Oncology
  • Immunology
  • Bioinformatics

Background:

  • Lung cancer is a leading cause of mortality with poor immunotherapy response due to limited tumor recognition.
  • Current neoantigen discovery methods miss low or heterogeneous expression targets.
  • ImmuniT is a novel platform designed for enhanced neoantigen discovery and validation.

Purpose of the Study:

  • To develop and validate ImmuniT, a platform for improved neoantigen discovery.
  • To identify a broader spectrum of neoantigens missed by conventional methods.
  • To enhance T cell activation for more effective lung cancer immunotherapy.

Main Methods:

  • Utilized a three-phase platform involving ex vivo tumor processing and autologous T cell co-culture.
  • Integrated mutational, transcriptomic, and HLA data using the nextneopi pipeline for neoantigen prediction.
  • Validated predicted neoantigens through MHC-epitope tetramer staining.

Main Results:

  • ImmuniT identified a wider range of neoantigens across five patient samples.
  • Demonstrated stronger in vitro T cell activation compared to standard approaches.
  • Confirmed two previously missed neoantigens elicited tumor-specific T cell responses in one patient.

Conclusions:

  • ImmuniT shows potential to broaden the repertoire of actionable tumor antigens.
  • The platform can improve personalized immunotherapy strategies for non-responsive patients.
  • Enhanced neoantigen discovery may overcome limitations in current lung cancer treatments.